GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Other Gross PPE

Y-Biologics (XKRX:338840) Other Gross PPE : ₩662 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Other Gross PPE?

Y-Biologics's Other Gross PPE for the quarter that ended in Mar. 2024 was ₩662 Mil.

Y-Biologics's quarterly Other Gross PPE increased from Sep. 2023 (₩548 Mil) to Dec. 2023 (₩635 Mil) and increased from Dec. 2023 (₩635 Mil) to Mar. 2024 (₩662 Mil).

Y-Biologics's annual Other Gross PPE increased from Dec. 2020 (₩962 Mil) to Dec. 2021 (₩1,746 Mil) but then declined from Dec. 2021 (₩1,746 Mil) to Dec. 2022 (₩903 Mil).


Y-Biologics Other Gross PPE Historical Data

The historical data trend for Y-Biologics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Other Gross PPE Chart

Y-Biologics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Gross PPE
Get a 7-Day Free Trial - 898.19 961.72 1,746.31 903.15

Y-Biologics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only 10,060.79 745.07 548.26 634.62 661.92

Y-Biologics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Y-Biologics (XKRX:338840) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR
Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines